Anthera Announces Update Call Regarding Vial Problems
HAYWARD, Calif., Dec. 9, 2010 /PRNewswire/ -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it will hold a conference call to provide an update on the ongoing investigation and remediation plans relating to vial problems in the PEARL-SC clinical study.
Conference Call Access: |
||
Date: |
December 14, 2010 |
|
Time: |
5:00 pm Eastern Time |
|
Domestic Dial-in: |
(877) 312-8807 |
|
International Dial-in: |
(253) 237-1190 |
|
Conference ID: |
29519371 |
|
The slides associated with the call can be accessed by logging into the live webcast at www.anthera.com.
To access the 24-hour audio replay, U.S. and Canadian participants may dial (800) 642-1687; international participants may dial (706) 645-9291. The conference ID for the replay is 29519371. The audio replay will be available until December 21, 2010. This conference call will be webcast live and archived on Anthera's website until December 14, 2011, www.anthera.com.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease (CAD). Anthera's Phase 2 product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BAFF, which has been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. For more information, please visit www.anthera.com.
CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., [email protected] or 510-856-5586.
SOURCE Anthera Pharmaceuticals, Inc.
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article